DarioHealth (NASDAQ:DRIO – Get Free Report) and Positron (OTCMKTS:POSC – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.
Earnings and Valuation
This table compares DarioHealth and Positron”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DarioHealth | $22.36 million | 2.29 | -$41.71 million | ($8.88) | -0.79 |
| Positron | $460,000.00 | 119.97 | -$10.60 million | ($0.33) | -5.09 |
Institutional & Insider Ownership
33.4% of DarioHealth shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by company insiders. Comparatively, 17.2% of Positron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for DarioHealth and Positron, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DarioHealth | 1 | 1 | 1 | 0 | 2.00 |
| Positron | 0 | 0 | 0 | 0 | 0.00 |
DarioHealth presently has a consensus target price of $10.50, suggesting a potential upside of 50.00%. Given DarioHealth’s stronger consensus rating and higher possible upside, equities research analysts plainly believe DarioHealth is more favorable than Positron.
Volatility and Risk
DarioHealth has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Positron has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500.
Profitability
This table compares DarioHealth and Positron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DarioHealth | -192.23% | -60.52% | -37.08% |
| Positron | -1,996.75% | -996.81% | -272.52% |
Summary
DarioHealth beats Positron on 10 of the 14 factors compared between the two stocks.
About DarioHealth
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
About Positron
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.
